03:56
Unknown
Cadila, India’s fourth largest healthcare Group and an innovation-led global healthcare provider and IDRI a Seattle-based non-profit research and product development organization has collaborated on the production and clinical development of IDRl ‘s visceral leishmaniasis (VL) vaccine candidate, designed to prevent the deadly parasitic disease.
Posted in: Indian Market Tips
0 comments:
Post a Comment